Alzheimer's study shows ketone bodies help clear misfolded proteins

Mechanism and Findings Discussed

• Study suggests ketone bodies may help clear misfolded proteins and improve proteostasis in aging and Alzheimer’s brains.
• Commenters highlight that the animal work used ketone esters, implying a potential “drug-like” route rather than relying solely on diet/fasting.
• Cited early human studies where ketogenic compounds improved cognitive scores in mild–moderate Alzheimer’s, but details and effect size are not deeply discussed.
• Exogenous ketones (e.g., BHB salts) are mentioned as a possible way to raise ketones without strict diets; some users report cognitive benefits (e.g., for “brain fog”), but this is purely anecdotal.

Fasting, Ketosis, and Practical Questions

• Strong interest in whether fasting can prevent/reduce Alzheimer’s risk and what schedule matters: daily 14–18h, 24–48h fasts, or multi‑day fasts.
• Disagreement on how long it takes to produce ketones: some say “multi-day,” others claim nightly ketone production if evening eating is avoided or carbs are restricted.
• Debate over whether intermittent fasting during Ramadan is enough; concerns that typical patterns (daytime fast, evening carb loading) may not induce ketosis.

Keto Diet: Experiences, Benefits, Risks

• Many report improved focus, reduced hunger, anti‑inflammatory effects, and easier long‑term adherence than moderate-carb dieting.
• Others find keto unsustainable socially or ethically (e.g., issues with meat sourcing) or psychologically (worsened mood, depression).
• Short-term “keto flu” and temporary cognitive fuzziness are commonly reported.
• Some long‑term users report worrying lab results, panic attacks, or problems potentially related to nutrient/omega‑6 imbalance, prompting caution about extreme or poorly planned keto.
• Emphasis from some that electrolyte and micronutrient supplementation is necessary.

Alzheimer’s Etiology and Alternative Hypotheses

• Several commenters frame Alzheimer’s as possibly linked to metabolic dysfunction (“type 3 diabetes”), insulin dysregulation, lipids, inflammation, or infections.
• Mentions of associations with GLP‑1 drugs, nicotine, appetite suppressants, and even BCG vaccination, but all as tentative, competing hypotheses.
• Significant skepticism about decades of amyloid‑centric research and known fraud, with concern the field may have chased the wrong target.

Patient Experience, Suffering, and Ethics

• Intense debate on whether people with advanced Alzheimer’s “don’t suffer” versus being unable to communicate significant distress.
• Multiple anecdotes of fear, confusion, panic attacks, attempts to “go home,” and unrecognized pain (e.g., untreated infections), suggesting suffering can be substantial.
• Others report patients who appear content, joking, or unaware; caregivers stress variability and the importance of vigilance for nonverbal signs of pain.
• Some see Alzheimer’s as a strong argument for assisted dying, given the prolonged decline and impact on families.

Meta: Research Access and Discussion Quality

• Mixed views on Hacker News as a venue: some see it as one of the few usable lay forums; others recommend going straight to journals and tools like PubMed RSS.
• Complaints about paywalls, difficulty interpreting primary literature, and limited access to knowledgeable clinicians for nuanced prevention discussions.